Log in
Enquire now
Iconic Therapeutics

Iconic Therapeutics

A pharmaceutical company developing tissue factor therapies for the treatment of cancer and diseases.

OverviewStructured DataIssuesContributors

Contents

iconictherapeutics.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Internal medicine
Internal medicine
Cancer
Cancer
Therapy
Therapy
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Healthcare
Healthcare
...
Location
South San Francisco, California
South San Francisco, California
0
San Francisco
San Francisco
B2X
B2B
B2B
0
CEO
‌
William Greene
0
Founder
‌
Michael Sherman
‌
Kirk Dornbush
AngelList URL
angel.co/iconic-therapeutics
Pitchbook URL
pitchbook.com/profiles.../56388-43
Email Address
info@iconictherapeutics.com0
Phone Number
+165043710000
Full Address
701 Gateway Blvd Suite 100, South San Francisco, CA 940800
Investors
MPM Capital
MPM Capital
H.I.G. Growth Partners
H.I.G. Growth Partners
0
H.I.G. BioVentures
H.I.G. BioVentures
Xeraya Capital
Xeraya Capital
ATDC
ATDC
0
Elm Street Ventures
Elm Street Ventures
Founded Date
2002
Fax Number
(650) 246-90110
Total Funding Amount (USD)
32,500,000
Latest Funding Round Date
August 9, 2016
Competitors
CODA Biotherapeutics
CODA Biotherapeutics
InterVenn Biosciences
InterVenn Biosciences
CytomX Therapeutics
CytomX Therapeutics
0
Sutro Biopharma
Sutro Biopharma
Latest Funding Type
Series C
Series C
Wellfound ID
iconic-therapeutics
Country
United States
United States
0

Other attributes

Company Operating Status
Active

Iconic Therapeutics is a clinical-stage biopharmaceutical company based in San Francisco focused on retinal disease and cancer. The company's expertise lies in tissue factor (TF) biology. TF is a protein that plays a key role in inflammation and pathological angiogenesis (the formation of abnormal new blood vessels). Iconic Therapeutics is building a new class of TF therapeutics (mAB) in which the protein is overexposed, pursuing promising opportunities such as treating wet age-related macular degeneration (AMD) and certain solid tumors.

In May 2018, in the area of opthalmology, Iconic's first-generation fusion protein (ICON-1) has demonstrated target engagement, biologic activity, and the ability to impact clinical endpoints in a controlled Phase 2 trial. It is a fusion protein that binds to TF overexposed in the retina and the choroidal neovascularization (CNV) of AMD patients. The antibody is expected to enter formal IND-enabling studies in 2019.

In the area of cancer, TF overexpression on tumors, tumor vasculature, and the tumor microenvironment is a key attribute of multiple solid tumors. Iconic's propriety antibody drug conjugate (ADC), mAb targets TF without interfering with blood clotting. This ADC is expected to enter formal IND-enabling studies in 2019 as well.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Iconic Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.